Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate the Diagnostic Efficacy and Safety of INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

NCT06922929 is registered in ClinicalTrials.gov with Yunhe Pharmaceutical (Tianjin) Co., Ltd as lead sponsor.

NCT NCT06922929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06922929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate the Diagnostic Efficacy and Safety of INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
Lead sponsor
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
April 30, 2025
Completion date
April 30, 2027
Enrollment
110 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer recurrent